Nucor earnings beat by $0.08, revenue fell short of estimates
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM) will host its Frontiers in Brain Health R&D Day on July 21, 2025, the biopharmaceutical company announced Monday.
The event, scheduled to begin at 11:00 a.m. Eastern Time in New York City, will showcase the company’s late-stage central nervous system (CNS) pipeline. Key opinion leaders in the medical field will discuss Axsome’s current neurology and psychiatry indications, while management will provide overviews of clinical development programs. The company has demonstrated impressive revenue growth of 72% and maintains strong gross profit margins above 91%, according to InvestingPro data.
Axsome’s portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine. The company also has multiple late-stage development programs targeting neurological and psychiatric conditions.
The R&D Day is primarily intended for institutional investors and sell-side analysts, with limited space available. A live webcast will be accessible to the public through the company’s website.
According to the press release statement, Axsome focuses on developing treatments with novel mechanisms of action for CNS conditions that affect over 150 million people in the United States.
The announcement comes as Axsome continues to market its approved products SUNOSI, AUVELITY, and SYMBRAVO while advancing its pipeline of CNS-focused drug candidates.
In other recent news, Axsome Therapeutics has faced a significant development with the U.S. Food and Drug Administration (FDA) issuing a Refusal to File (RTF) letter for its New Drug Application (NDA) for AXS-14, intended for fibromyalgia treatment. The FDA cited the inadequacy of one of the two placebo-controlled trials due to its 8-week primary endpoint and flexible-dose paradigm. In response, Axsome plans to conduct an additional trial with a 12-week endpoint and fixed-dose approach starting in the fourth quarter of 2025. Despite this setback, Piper Sandler and H.C. Wainwright have maintained their Overweight and Buy ratings, respectively, reflecting a continued positive outlook on Axsome’s potential. Oppenheimer also maintained its Outperform rating, though it slightly lowered its price target to $183 from $185. The firm believes the market had not heavily factored in AXS-14, suggesting limited impact on the stock. Meanwhile, Morgan Stanley has assumed coverage with an Overweight rating, focusing on Axsome’s ongoing launch of Auvelity for major depressive disorder. The investment bank projects significant sales growth for Axsome’s pipeline by 2030, indicating a strong outlook despite the recent FDA setback.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.